Research Australia supports the objective of encouraging early-stage private investment in innovative Australian businesses. The HMR sector is particularly dependent on patient capital because the pathway from discovery to commercialisation can be long, expensive and uncertain, particularly for biotechnology, medical technology, therapeutics and other regulated health innovations.
You can read our submission in response to the “Better targeting the Research and Development Tax Incentive – Exposure Draft Legislation” here.
Read our submission in response to the “Innovative Business CGT Concession – exposure draft legislation” here.
